Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

Clinical trial NCT06718244 · RECRUITING

Trial details

NCT number: NCT06718244
Sponsor: Ruijin Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukemia

Start date: 2024-12-10
Primary completion: 2029-12-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.